A

AptaBio Therapeutics Inc
KOSDAQ:293780

Watchlist Manager
AptaBio Therapeutics Inc
KOSDAQ:293780
Watchlist
Price: 9 250 KRW 0.33%
Market Cap: 248.6B KRW

Intrinsic Value

The intrinsic value of one AptaBio Therapeutics Inc stock under the Base Case scenario is 925.93 KRW. Compared to the current market price of 9 250 KRW, AptaBio Therapeutics Inc is Overvalued by 90%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
925.93 KRW
Overvaluation 90%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation History
AptaBio Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about AptaBio Therapeutics Inc?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is AptaBio Therapeutics Inc valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for AptaBio Therapeutics Inc.

Explain Valuation
Compare AptaBio Therapeutics Inc to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about AptaBio Therapeutics Inc?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
AptaBio Therapeutics Inc

Current Assets 26.7B
Cash & Short-Term Investments 22.6B
Receivables 1.6B
Other Current Assets 2.6B
Non-Current Assets 43B
Long-Term Investments 31.9B
PP&E 5.8B
Intangibles 1.5B
Other Non-Current Assets 3.8B
Current Liabilities 18.4B
Accounts Payable 106.7m
Accrued Liabilities 619m
Other Current Liabilities 17.6B
Non-Current Liabilities 3.9B
Long-Term Debt 93m
Other Non-Current Liabilities 3.8B
Efficiency

Free Cash Flow Analysis
AptaBio Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
AptaBio Therapeutics Inc

Revenue
3.1B KRW
Cost of Revenue
-2.5B KRW
Gross Profit
643.2m KRW
Operating Expenses
-19.9B KRW
Operating Income
-19.2B KRW
Other Expenses
-6B KRW
Net Income
-25.2B KRW
Fundamental Scores

Profitability Score
Profitability Due Diligence

AptaBio Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Operating Margin is Increasing
Net Margin is Increasing
Healthy Gross Margin
Low 3Y Average Gross Margin
16/100
Profitability
Score

AptaBio Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

AptaBio Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Average Altman Z-Score
59/100
Solvency
Score

AptaBio Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
AptaBio Therapeutics Inc

There are no price targets for AptaBio Therapeutics Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

AptaBio Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AptaBio Therapeutics Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one AptaBio Therapeutics Inc stock?

The intrinsic value of one AptaBio Therapeutics Inc stock under the Base Case scenario is 925.93 KRW.

Is AptaBio Therapeutics Inc stock undervalued or overvalued?

Compared to the current market price of 9 250 KRW, AptaBio Therapeutics Inc is Overvalued by 90%.

Back to Top